7 -1 (75) 2025 - Sh.S. Sobirova, G.M. Tulaboeva - FEATURES OF CARDIORENAL SYNDROME

FEATURES OF CARDIORENAL SYNDROME

Sh.S. Sobirova - Bukhara State Medical Institute named after Abu Ali ibn Sina

G.M. Tulaboeva - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

The article provides evidence-based arguments highlighting the necessity of a highly qualified integrated approach to the treatment strategies for hypertension and chronic heart failure (CHF) in patients with kidney pathology. It is demonstrated that renal hypoperfusion may be an early marker of hypertension or CHF. Pathogenetic treatment methods play a significant role in preventing cardiovascular and renal complications.

Keywords: ischemic heart disease, chronic kidney disease, myocardial infarction, atrial fibrillation.

First page

26

Last page

28

For citation:Sh.S. Sobirova, G.M. Tulaboeva - FEATURES OF CARDIORENAL SYNDROME//New Day in Medicine 1(75)2025 26-28 https://https://newdayworldmedicine.com/en/new_day_medicine/1-75-2025

List of References

  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. //Kidney Int Suppl. 2013;3:1-150.
  2. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. //Kidney Int Suppl. 2012;2:337-414.
  3. Major R.W., Cheng M.R.I., Grant R.A. et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. //PLoS One. 2018;13(3):e0192895. DOI: 10.1371/journal.pone.0192895.
  4. Löfman I., Szummer K., Hagerman I. et al. Prevalence and prognostic impact of kidney disease on heart failure patients. //Open Heart. 2016;3:e000324. DOI: 10.1136/ openhrt-2015-000324.
  5. Hillege H.L., Nitsch D., Pfeffer M.A. et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. //Circulation. 2006;113:671-678. DOI: 10.1161/Circulationaha.105.580506.
  6. Levey A.S., Stevens L.A., Schmid C.H. et al. A new equation to estimate glomerular filtration rate. //Ann Intern Med. 2009;150(9):604-612. DOI: 10.7326/0003-4819-150-9-200905050-00006.
  7. Ghali J.K., Wikstrand J., van Veldhuisen D.J. et al. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). //J Card Fail. 2009;15:310-318. DOI: 10.1016/j.cardfail.2008.11.003.
  8. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBISII): a randomised trial. //Lancet. 1999;353:9-13. PMID: 10023943.
  9. Damman K., Tang W.H., Felker G.M. et al. Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. //J Am Coll Cardiol. 2014;63:853-871. DOI: 10.1016/j.jacc.2012.07.048.
  10. Molnar M., Kalantar-Zadeh K., Lott E. et al. Angiotensin-Converting Enzyme Inhibitor, Angiotensin Receptor Blocker Use, and Mortality in Patients With Chronic Kidney Disease. //Am Coll Cardiol 2014;63:650-658. DOI: 10.1016/j.jacc.2013.10.050.
  11. Sica D.A., Gehr T.W.B., Kelleher N., Blumenthal M. Fosinopril: Emerging Considerations and Implications for Angiotensin-Converting Enzyme Inhibitor Therapy. //Cardiovascular Drug Reviews. 1998;(16)4:319-345.
  12. Erhardt L., MacLean A., Ilgenfritz J. et al. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. //Eur Heart J. 1995;16(12):1892-1899. DOI: 10.1093/oxfordjournals.eurheartj.a060844.

    file

    download